Oliver Lagore Vanvalin Investment Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25	Closed	-$2.32K	–	775
2024 Q2	$2.32K	Buy	+25	New	+$2.24K	﹤0.01%	590
2023 Q4	–	Sell	-3,641	Closed	-$266K	–	884
2023 Q3	$266K	Sell	3,641 -1,676	-32%	-$134K	0.11%	106
2023 Q2	$442K	Sell	5,317 -2,612	-33%	-$218K	0.16%	91
2023 Q1	$604K	Sell	7,929 -20,862	-72%	-$1.73M	0.26%	42
2022 Q4	$2.39M	Buy	28,791 +25,589	+799%	+$2.07M	1.35%	16
2022 Q3	$254K	Buy	3,202 +196	+7%	+$16.5K	0.16%	78
2022 Q2	$223K	Buy	+3,006	New	+$226K	0.13%	84

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's XBI Position: Q3 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 25 shares — an estimated $2.32K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in XBI in Q2 2022 and held it in 7 quarters. The position peaked at $2.39M in Q4 2022. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Oliver Lagore Vanvalin Investment Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 25 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $2.32K.
Oliver Lagore Vanvalin Investment Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 7 quarters.
Oliver Lagore Vanvalin Investment Group's State Street SPDR S&P Biotech ETF position peaked at $2.39M in Q4 2022.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q3 2024, filed 4 Nov 2024.